Retatrutide, a new injectable medication that activates three hormone pathways, significantly improves blood sugar control and causes substantial weight loss in people with type 2 diabetes. According to Gram Research analysis of this 537-person clinical trial, the highest dose reduced blood sugar levels by 1.94% and caused weight loss of 15.3% over 40 weeks, compared to 0.81% blood sugar reduction and 2.6% weight loss with placebo. The most common side effects were mild stomach issues that improved over time.
A major clinical trial tested retatrutide, a new injectable medication that works on three different hormone pathways in the body to help control type 2 diabetes. In this 40-week study of 537 people with diabetes that wasn’t well-controlled by diet and exercise alone, those receiving retatrutide showed significant improvements in blood sugar control and lost substantial weight. The highest dose reduced blood sugar levels by nearly 2% and caused weight loss of up to 15%, compared to minimal changes in the placebo group. Side effects were mostly mild stomach issues that improved over time, making this a promising new treatment option for people struggling to manage their diabetes.
Key Statistics
A 2026 randomized controlled trial of 537 people with type 2 diabetes found that retatrutide 12 mg reduced HbA1c (long-term blood sugar measure) by 1.94% compared to 0.81% with placebo, a statistically significant difference of 1.12 percentage points.
In the same 40-week trial, participants receiving retatrutide 12 mg lost an average of 15.3% of their body weight, compared to 2.6% weight loss in the placebo group—a difference of 12.7 percentage points.
The TRANSCEND-T2D-1 trial found that only 2-5% of retatrutide users discontinued treatment due to side effects, primarily mild gastrointestinal symptoms that improved over time, with no cases of severe low blood sugar reported.
Among 537 participants in this phase 3 trial, 91% completed the full 40-week treatment period on the study drug, and 94% completed the entire study, indicating good tolerability and adherence.
The Quick Take
- What they studied: Whether a new injectable drug called retatrutide could better control blood sugar levels in people with type 2 diabetes who weren’t getting good results from diet and exercise alone.
- Who participated: 537 adults (average age 49 years) with type 2 diabetes that wasn’t well-controlled. About 55% were women and 45% were men. Most were overweight or obese, with an average BMI of 36. They were randomly split into four groups: three received different doses of retatrutide, and one received a placebo (fake injection).
- Key finding: All three doses of retatrutide significantly lowered blood sugar levels, with the highest dose (12 mg) reducing HbA1c (a measure of long-term blood sugar control) by 1.94%, compared to only 0.81% with placebo. The same highest dose caused weight loss of 15.3%, versus 2.6% with placebo.
- What it means for you: If you have type 2 diabetes that diet and exercise alone haven’t controlled well, retatrutide could be an effective new option. However, it does cause stomach side effects in many people, though these typically improve over time. Talk to your doctor about whether this medication might be right for you.
The Research Details
This was a phase 3 randomized controlled trial, which is the gold standard for testing new medications. Researchers recruited 537 adults with type 2 diabetes from 48 medical centers across the USA, Mexico, and India. Participants were randomly assigned to receive one of three doses of retatrutide (4 mg, 9 mg, or 12 mg) or a placebo injection once per week for 40 weeks. Neither the participants nor the researchers knew who was receiving the real drug versus placebo, which helps prevent bias.
Retatrutide is a triple-action medication that activates three different hormone receptors in the body: GIP, GLP-1, and glucagon receptors. These hormones naturally help regulate blood sugar, appetite, and metabolism. By activating all three pathways simultaneously, retatrutide appears to work more powerfully than medications that target just one or two of these pathways.
The study measured blood sugar control using HbA1c (a test that shows average blood sugar over three months) and tracked weight changes. Researchers also carefully monitored side effects throughout the 40-week period.
This research approach is important because it tests retatrutide as a standalone treatment, not combined with other diabetes medications. This helps doctors understand exactly what the drug can do on its own. The randomized, double-blind design eliminates bias and provides the strongest evidence possible. Testing in multiple countries also shows the results apply to diverse populations.
This study has several strengths: it was published in The Lancet, one of the world’s most prestigious medical journals; it was a large, well-designed randomized controlled trial; 91% of participants completed the full treatment period; and the results were consistent across all three doses tested. The study was funded by Eli Lilly, the drug’s manufacturer, which is standard but means the company had input into the research design. However, the independent journal review process and the transparent reporting of all results, including side effects, suggest the findings are reliable.
What the Results Show
Retatrutide produced dose-dependent improvements in blood sugar control. The 4 mg dose reduced HbA1c by 1.69%, the 9 mg dose by 1.86%, and the 12 mg dose by 1.94%, all significantly better than placebo’s 0.81% reduction. These differences were all statistically significant (p<0.0001), meaning they’re extremely unlikely to have occurred by chance.
Weight loss was substantial and also dose-dependent. Participants receiving 4 mg lost an average of 11.5% of their body weight, those on 9 mg lost 13.9%, and those on 12 mg lost 15.3%. In comparison, the placebo group lost only 2.6% of their body weight. For someone weighing 200 pounds, the highest dose would mean losing about 30 pounds over 40 weeks.
These improvements occurred in people whose diabetes wasn’t adequately controlled by lifestyle changes alone, suggesting retatrutide fills an important gap in treatment options. The benefits were consistent across the diverse population studied, including people from the USA, Mexico, and India.
Beyond blood sugar and weight, the study found that retatrutide was well-tolerated overall. The most common side effects were gastrointestinal issues like nausea, vomiting, and diarrhea—effects typical of GLP-1 receptor agonists. Importantly, these side effects were generally mild to moderate and tended to improve as treatment continued. Only 2-5% of participants stopped taking retatrutide because of side effects, compared to 0% in the placebo group. No cases of severe low blood sugar (hypoglycemia) occurred in any group, which is reassuring since some diabetes medications carry this risk. Two deaths occurred during the study, both in the lowest-dose group, but investigators determined these were unrelated to the medication.
Retatrutide represents a new generation of diabetes treatment. Previous GLP-1 receptor agonists (like semaglutide) have shown good results, but retatrutide’s triple-action approach appears to produce greater weight loss and potentially better blood sugar control. The weight loss seen here (up to 15%) is comparable to or exceeds what’s been observed with other newer diabetes and obesity medications. This positions retatrutide as a potentially important addition to the treatment toolkit, particularly for people with diabetes who are also overweight or obese.
The study lasted only 40 weeks, so we don’t know about long-term effects beyond this timeframe. The study population was relatively young (average age 49) and mostly overweight or obese, so results may not apply equally to older adults or those of normal weight. Because participants had relatively early-stage diabetes (average duration 2.5 years), we don’t know how well retatrutide works in people with long-standing diabetes. The study was funded by the drug’s manufacturer, which could introduce bias, though the transparent reporting of results and side effects suggests this wasn’t a major issue. Finally, this was a monotherapy trial (retatrutide alone), so we don’t yet know how it works when combined with other diabetes medications.
The Bottom Line
For people with type 2 diabetes inadequately controlled by diet and exercise alone, retatrutide appears to be an effective treatment option with strong evidence (high confidence). It significantly improves blood sugar control and produces substantial weight loss. However, expect gastrointestinal side effects, particularly early in treatment. Discuss with your doctor whether retatrutide is appropriate for you, especially if you have a history of thyroid problems or pancreatitis, as GLP-1 agonists carry theoretical risks in these populations. This medication requires weekly injections, so commitment to the injection schedule is necessary.
Retatrutide is most relevant for adults with type 2 diabetes whose blood sugar remains elevated despite diet and exercise efforts. It’s particularly valuable for people who are also overweight or obese, since it addresses both conditions. People who prefer injectable medications over pills and can tolerate temporary stomach side effects are good candidates. This medication is NOT appropriate for people with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2, or for pregnant women. People with severe kidney or liver disease should discuss use with their doctor.
Blood sugar improvements typically appear within the first few weeks of treatment, though the full benefit takes several weeks to develop. Weight loss begins gradually and accelerates over the first 8-12 weeks. Most gastrointestinal side effects appear in the first 1-2 weeks but improve significantly by week 4-6 as the body adjusts. The study lasted 40 weeks, so expect to see meaningful results within 2-3 months, with continued improvements over several months of treatment.
Frequently Asked Questions
How much weight can you lose with retatrutide for diabetes?
In a 40-week clinical trial, people taking retatrutide 12 mg lost an average of 15.3% of their body weight—about 30 pounds for someone weighing 200 pounds. Lower doses produced less weight loss: 11.5% at 4 mg and 13.9% at 9 mg.
What are the side effects of retatrutide injections?
The most common side effects are gastrointestinal issues like nausea, vomiting, and diarrhea. These are typically mild to moderate and improve over time as your body adjusts. Only 2-5% of people stopped taking the medication due to side effects. No severe low blood sugar occurred.
How does retatrutide work differently from other diabetes medications?
Retatrutide activates three hormone pathways (GIP, GLP-1, and glucagon) simultaneously, whereas most other newer diabetes drugs target only one or two. This triple action appears to produce greater improvements in blood sugar control and weight loss than single-pathway medications.
Is retatrutide approved by the FDA for type 2 diabetes?
This trial was completed in 2025, and the results support retatrutide’s potential as an effective diabetes treatment. However, FDA approval status may vary by indication and region, so check with your doctor or the FDA website for current approval information.
How long does it take to see results from retatrutide?
Blood sugar improvements typically appear within the first few weeks, while weight loss begins gradually and accelerates over 8-12 weeks. Most gastrointestinal side effects appear early but improve significantly by week 4-6. Meaningful results are usually visible within 2-3 months of treatment.
Want to Apply This Research?
- Track weekly HbA1c trends (if testing at home with a continuous glucose monitor) or schedule monthly lab tests to monitor HbA1c changes. Also log weekly weight and note any gastrointestinal symptoms (nausea, vomiting, diarrhea) to identify patterns and confirm side effects are improving over time.
- Set a weekly reminder for your injection day and time to ensure consistent dosing. Log any side effects immediately after injection to track whether they’re improving. Record your weight weekly at the same time of day to monitor progress. Use the app to document how you’re feeling and any dietary adjustments you’re making to manage stomach symptoms.
- Create a dashboard showing your HbA1c trend over months, weight loss progress toward your goal, and a symptom calendar tracking gastrointestinal side effects. Set monthly check-in reminders to review your progress and note any changes in how you’re feeling. Share this data with your doctor at regular appointments to assess whether retatrutide is working well for you and whether dose adjustments are needed.
This article summarizes clinical trial results and is for educational purposes only. It does not constitute medical advice. Retatrutide is a prescription medication that should only be used under the supervision of a qualified healthcare provider. Do not start, stop, or change any diabetes medication without consulting your doctor. People with a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, or pancreatitis should not use GLP-1 receptor agonists. Pregnant women and those planning pregnancy should discuss this medication with their healthcare provider. Individual results may vary based on your specific health situation, other medications, and lifestyle factors. Always discuss potential benefits and risks with your healthcare team before starting any new treatment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.